Focus: Centessa Pharmaceuticals is an umbrella company that acquires and develops drug candidates across neurology and rare diseases, with a diversified pipeline spanning early to late-stage programs. The company operates as a portfolio manager with 18 active roles across clinical, regulatory, and manufacturing functions.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Cooling — net -7 jobs in 30d
7 added, 14 removed. Slower than typical.
Centessa is an attractive mid-stage opportunity for those seeking pipeline diversity and clinical development experience, but the pending Lilly acquisition introduces organizational uncertainty—clarify integration timelines and role security in interviews.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Centessa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Centessa Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: ELI LILLY & Co (LLY) (CIK 0000059478) — EX-99
EX-99
LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal - MSN
LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal MSN
Centessa Pharmaceuticals agrees to Eli Lilly acquisition at 40% premium - MSN
Centessa Pharmaceuticals agrees to Eli Lilly acquisition at 40% premium MSN
8-K Filing: First Tracks Biotherapeutics, Inc. (TRAX) (CIK 0002091349) — EX-99.1
EX-99.1
Lilly to Acquire Centessa Pharmaceuticals - Contract Pharma
Lilly to Acquire Centessa Pharmaceuticals Contract Pharma
American pharmaceutical company Eli Lilly acquires British Centessa for $7.8 billion - AKM.RU
American pharmaceutical company Eli Lilly acquires British Centessa for $7.8 billion AKM.RU
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Coagulation and platelet biology at the intersection of health and disease: illustrated capsules of the 11th Symposium on Hemostasis at the University of North Carolina.
Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo